The approvals were based on results from the JUNIPERA trial, which showed secukinumab reduced the risk of flare and disease activity when compared with placebo over 2 years in pediatric patients with ERA and JPsA.
The Committee for Medicinal Products for Human Use (CHMP) issues a positive opinion to expand Novartis secukinumab indication to enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA).
“Understanding the extent of the co-occurrence and identifying factors associated with an increased susceptibility could be relevant to implement case-finding strategies in specific at-risk populations," investigators stated.
Limited physical function, fatigue, mental health issues (resulting from chronic disease), and medication issues can further affect the ability of children with rheumatic disease from performing well in school.
Karen Onel, MD, one of the lead investigators of the ACR's recent JIA treatment guidelines updates, explains important changes, treating patients with glucocorticoids, and the continued unmet needs in pediatric rheumatology.